The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Drug Therapy of Elderly Diabetic Patients

노인 당뇨병 환자의 약물 치료

  • Hong, Eun-Gyoung (Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine)
  • 홍은경 (한림대학교 의과대학 강남성심병원 내과)
  • Published : 2011.06.01
⟨ Previous Next ⟩

Abstract

The worldwide prevalence of type 2 diabetes increases with age and almost 40% of men and more than 50% of women in Korean diabetic patients are over the age of 65. Recent clinical trials suggest that early intensive glycemic control reduces chronic complications associated with morbidity and mortality in type 2 diabetic patients. The principles of management of type 2 diabetes in the elderly are not different from those in middle-aged patients. However, before initiating any form of glucose-lowering therapy in the elderly it is necessary to assess the patient overall health status, coexisting illnesses, social environment, psychological well-being and degree of cognitive function. Furthermore, it should be considered to keep glucose control on individualized target without the risk of hypoglycemia in elderly diabetic patients due to the more deleterious and serious conditions. The old and more recent oral glucose-lowering agents and insulins are effective in the elderly patient. The characteristics and side effects of diabetic agents should be carefully reviewed by clinician before starting any form of medication in the elderly.

Keywords

References

  1. Rauseo A, Pacilli A, Palena A, De Cosmo SA. Management of type 2 diabetes in geriatric patients. J Nephrol 2010;23(Suppl 15):S72-S79.
  2. 당뇨병 기초통계연구 Task Force Team 보고서. Diabetes 2007.
  3. American Diabetes Association: Standards of medical care in diabetes: 2010. Diabetes Care 2010;33(Suppl 1):S11-S61. https://doi.org/10.2337/dc10-S011
  4. Hazzard's Geriatric medicine and gerontology. 6th ed. New York: McGraw-Hill Companies, 2009.
  5. 대한당뇨병학회 노인당뇨병소연구회. 노인당뇨병. 제2판. 서울;고려의학, 2010.
  6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865. https://doi.org/10.1016/S0140-6736(98)07037-8
  7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012. https://doi.org/10.1001/jama.281.21.2005
  8. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of type 2 diabetes? Int J Obes Relat Metab Disord 2000;24(Suppl 3):S21-S31.
  9. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A diabetes outcome progression trial (ADOPT). Diabetes Care 2008;31:845-851. https://doi.org/10.2337/dc07-2270
  10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471. https://doi.org/10.1056/NEJMoa072761
  11. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135. https://doi.org/10.1016/S0140-6736(09)60953-3
  12. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5
  13. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-7405.
  14. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:317-326. https://doi.org/10.1089/dia.2006.0024
  15. Chaisson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077. https://doi.org/10.1016/S0140-6736(02)08905-5
  16. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005;34:77-98. https://doi.org/10.1016/j.ecl.2004.12.002
  17. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes: HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-1136. https://doi.org/10.2337/diacare.23.8.1130